Envista Holdings Corporation (NYSE:NVST) Receives Average Rating of “Hold” from Analysts

Envista Holdings Corporation (NYSE:NVST) has received an average rating of “Hold” from the fifteen brokerages that are currently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $28.8333.

A number of equities analysts have commented on the stock. Piper Sandler restated a “neutral” rating and set a $25.00 price objective (up from $21.00) on shares of Envista in a research report on Friday, February 6th. Leerink Partners set a $35.00 price objective on shares of Envista and gave the stock an “outperform” rating in a research report on Friday, February 6th. Zacks Research downgraded shares of Envista from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Weiss Ratings downgraded shares of Envista from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 11th. Finally, UBS Group upped their price objective on shares of Envista from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 3rd.

Envista Stock Down 0.4%

NVST stock opened at $23.14 on Thursday. The company has a fifty day moving average price of $25.82 and a 200 day moving average price of $24.24. Envista has a 12 month low of $16.41 and a 12 month high of $30.42. The company has a market cap of $3.76 billion, a price-to-earnings ratio of 56.43, a price-to-earnings-growth ratio of 1.45 and a beta of 0.92. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.44 and a quick ratio of 2.06.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.31 by $0.05. The firm had revenue of $705.50 million during the quarter, compared to the consensus estimate of $680.04 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. Envista’s revenue for the quarter was up 14.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Sell-side analysts expect that Envista will post 1.43 earnings per share for the current year.

Hedge Funds Weigh In On Envista

A number of large investors have recently made changes to their positions in the stock. Parallel Advisors LLC increased its holdings in shares of Envista by 13.1% in the 4th quarter. Parallel Advisors LLC now owns 3,175 shares of the company’s stock valued at $69,000 after purchasing an additional 367 shares in the last quarter. Bank of Montreal Can increased its holdings in shares of Envista by 1.4% in the 4th quarter. Bank of Montreal Can now owns 26,178 shares of the company’s stock valued at $568,000 after purchasing an additional 372 shares in the last quarter. Sepio Capital LP increased its holdings in shares of Envista by 1.2% in the 4th quarter. Sepio Capital LP now owns 31,632 shares of the company’s stock valued at $687,000 after purchasing an additional 374 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Envista by 2.9% in the 4th quarter. Deutsche Bank AG now owns 17,412 shares of the company’s stock valued at $378,000 after purchasing an additional 484 shares in the last quarter. Finally, State of Michigan Retirement System increased its holdings in shares of Envista by 1.5% in the 1st quarter. State of Michigan Retirement System now owns 39,463 shares of the company’s stock valued at $1,001,000 after purchasing an additional 600 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.